Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Standard BioTools Inc. (LAB)

0.6942 +0.0582 (+9.15%)
At close: November 9 at 4:00:01 PM EST
0.7190 +0.0248 (+3.57%)
After hours: November 9 at 4:07:14 PM EST
Trade LAB on Coinbase
Chart Range Bar
Loading chart for LAB
Chart does not reflect overnight price.
  • Previous Close 0.6360
  • Open 0.6372
  • Bid 0.4452 x 200
  • Ask 0.8320 x 200
  • Day's Range 0.6361 - 0.7179
  • 52 Week Range 0.5900 - 1.7200
  • Volume 730,104
  • Avg. Volume 1,208,307
  • Market Cap (intraday) 274.064M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0900
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 1.35
  • Moby Rating Neutral

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

www.standardbio.com

385

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LAB
45.77%
S&P 500 (^GSPC)
10.29%

1-Year Return

LAB
38.57%
S&P 500 (^GSPC)
12.20%

3-Year Return

LAB
65.80%
S&P 500 (^GSPC)
73.67%

5-Year Return

LAB
85.01%
S&P 500 (^GSPC)
61.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 20.1M
Earnings -21.52M
Profit Margin -107.07%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-30M
-20M
-10M
0
10M
20M
-150.0%
-100.0%
-50.0%
0.0%
50.0%

Analyst Insights

View More

Analyst Price Targets

1.35
1.35 Average
0.6942 Current
1.35 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/5/2025
Analyst TD Cowen
Rating Action Maintains
Rating Hold
Price Action Lowers
Price Target 1.55 -> 1.35

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    157.62%

  • Return on Assets (ttm)

    -5.03%

  • Return on Equity (ttm)

    -7.79%

  • Revenue (ttm)

    84.43M

  • Net Income Avi to Common (ttm)

    -37.23M

  • Diluted EPS (ttm)

    -0.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    461.11M

  • Total Debt/Equity (mrq)

    4.83%

  • Levered Free Cash Flow (ttm)

    166.87M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: